Zacks Research Issues Pessimistic Outlook for CORT Earnings

Corcept Therapeutics Incorporated (NASDAQ:CORT) – Investment analysts at Zacks Research dropped their Q1 2026 earnings per share (EPS) estimates for Corcept Therapeutics in a research report issued to clients and investors on Wednesday, January 14th. Zacks Research analyst Team now anticipates that the biotechnology company will post earnings per share of ($0.31) for the quarter, down from their prior estimate of $0.04. Zacks Research has a “Strong Sell” rating on the stock. The consensus estimate for Corcept Therapeutics’ current full-year earnings is $1.36 per share. Zacks Research also issued estimates for Corcept Therapeutics’ Q2 2026 earnings at ($0.06) EPS and FY2026 earnings at $0.43 EPS.

Corcept Therapeutics (NASDAQ:CORT) last announced its quarterly earnings results on Tuesday, November 4th. The biotechnology company reported $0.16 EPS for the quarter, missing the consensus estimate of $0.18 by ($0.02). The firm had revenue of $207.64 million for the quarter, compared to analyst estimates of $223.78 million. Corcept Therapeutics had a return on equity of 15.99% and a net margin of 14.19%.The business’s revenue was up 13.8% compared to the same quarter last year. During the same quarter in the prior year, the company earned $0.41 earnings per share.

Other research analysts have also issued research reports about the stock. Canaccord Genuity Group cut their price target on shares of Corcept Therapeutics from $140.00 to $99.00 and set a “buy” rating on the stock in a report on Friday, January 2nd. Wolfe Research downgraded shares of Corcept Therapeutics from a “peer perform” rating to an “underperform” rating and set a $30.00 target price on the stock. in a research note on Wednesday, December 31st. Wall Street Zen lowered shares of Corcept Therapeutics from a “buy” rating to a “hold” rating in a report on Saturday, October 18th. HC Wainwright lowered their price target on Corcept Therapeutics from $145.00 to $90.00 and set a “buy” rating for the company in a report on Friday, January 2nd. Finally, UBS Group assumed coverage on Corcept Therapeutics in a research note on Tuesday, December 16th. They set a “neutral” rating and a $95.00 price objective on the stock. Four research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and two have assigned a Sell rating to the company. Based on data from MarketBeat, Corcept Therapeutics currently has an average rating of “Hold” and an average price target of $80.83.

Corcept Therapeutics Stock Performance

NASDAQ CORT opened at $34.73 on Monday. The company has a debt-to-equity ratio of 0.01, a current ratio of 3.14 and a quick ratio of 3.07. Corcept Therapeutics has a 1-year low of $32.99 and a 1-year high of $117.33. The firm has a market capitalization of $3.65 billion, a P/E ratio of 39.47 and a beta of 0.23. The business’s 50-day simple moving average is $69.09 and its 200-day simple moving average is $72.25.

Insider Activity

In related news, insider Sean Maduck sold 20,000 shares of Corcept Therapeutics stock in a transaction on Monday, December 1st. The shares were sold at an average price of $79.52, for a total transaction of $1,590,400.00. Following the sale, the insider owned 7,904 shares of the company’s stock, valued at $628,526.08. The trade was a 71.67% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, insider Joseph Douglas Lyon sold 5,000 shares of the business’s stock in a transaction on Monday, December 1st. The stock was sold at an average price of $79.53, for a total transaction of $397,650.00. Following the completion of the transaction, the insider owned 10,277 shares in the company, valued at $817,329.81. This represents a 32.73% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 194,500 shares of company stock valued at $14,186,410 in the last 90 days. Company insiders own 20.80% of the company’s stock.

Institutional Investors Weigh In On Corcept Therapeutics

A number of hedge funds have recently bought and sold shares of CORT. AQR Capital Management LLC increased its holdings in Corcept Therapeutics by 546.9% during the 3rd quarter. AQR Capital Management LLC now owns 1,507,209 shares of the biotechnology company’s stock worth $125,264,000 after purchasing an additional 1,274,215 shares during the last quarter. Norges Bank acquired a new stake in shares of Corcept Therapeutics during the second quarter worth approximately $72,048,000. TD Asset Management Inc increased its stake in shares of Corcept Therapeutics by 16.6% in the third quarter. TD Asset Management Inc now owns 956,136 shares of the biotechnology company’s stock worth $79,464,000 after buying an additional 136,254 shares during the last quarter. JPMorgan Chase & Co. increased its stake in shares of Corcept Therapeutics by 223.4% in the third quarter. JPMorgan Chase & Co. now owns 849,864 shares of the biotechnology company’s stock worth $70,632,000 after buying an additional 587,053 shares during the last quarter. Finally, Epoch Investment Partners Inc. raised its holdings in Corcept Therapeutics by 10.7% in the third quarter. Epoch Investment Partners Inc. now owns 847,104 shares of the biotechnology company’s stock valued at $70,403,000 after acquiring an additional 81,700 shares in the last quarter. Institutional investors and hedge funds own 93.61% of the company’s stock.

Key Headlines Impacting Corcept Therapeutics

Here are the key news stories impacting Corcept Therapeutics this week:

• Positive Sentiment: Zacks Research raised its Q4 2027 EPS estimate for CORT to $1.29 from $1.12, a small upside to that specific quarter despite the firm’s overall bearish stance. Read More.
• Positive Sentiment: Zacks also nudged up its Q4 2026 EPS estimate to $0.49 from $0.43 — another isolated upward revision that could be seen as modestly supportive for near-term quarterly expectations. Read More.
• Neutral Sentiment: Coverage pieces are highlighting Corcept’s profit profile versus peers and discussing growth prospects; these help keep the company on investors’ radar but don’t change fundamentals by themselves. Read More.
• Neutral Sentiment: Industry comparisons (e.g., profitability vs. a faster-growing rival) provide context for valuation debates but are not immediate catalysts. Read More.
• Negative Sentiment: Zacks Research downgraded CORT from “hold” to a “strong sell” and trimmed several near-term and FY2027 EPS forecasts (multiple cuts to Q1–Q3 2026/2027 and a FY2027 cut to $3.21 from $3.35). The downgrade and lower multi-quarter estimates are a clear negative catalyst for sentiment and can pressure the stock. Read More.
• Negative Sentiment: Multiple law firms (Pomerantz, Schall, DJS) have announced investigations alleging potential misstatements or nondisclosures; the emergence of shareholder litigation risk typically weighs on investor sentiment and can create legal and reputational uncertainty. Read More. Read More. Read More.
• Negative Sentiment: An outside price-target cut was reported (a ~28% reduction to $92.82), which can recalibrate upside expectations and contribute to selling pressure from valuation-conscious investors. Read More.

About Corcept Therapeutics

Corcept Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing drugs that modulate the effects of cortisol, a hormone implicated in a range of severe metabolic, oncologic and psychiatric disorders. The company’s scientific platform centers on selectively targeting the glucocorticoid receptor to counteract the harmful consequences of excess cortisol, a strategy designed to address diseases with significant unmet medical needs.

The company’s flagship marketed product, Korlym (mifepristone), is approved in the United States for the treatment of hyperglycemia secondary to Cushing’s syndrome in patients who have type 2 diabetes or glucose intolerance and are not candidates for surgery.